By Kane Wu and Andrew Silver HONG KONG/SHANGHAI, Feb 13 (Reuters) - Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent ...

The world's top polluter crossed a critical energy transition threshold in 2025 by deploying more clean power capacity than ...

China has significantly increased its coal power capacity, reviving concerns about its climate-changing carbon emissions ...

Honda will shift its automobile development operations back under its R&D subsidiary, Honda R&D Co., Ltd., effective April 1, ...

We also discuss Tesla and Waymo's U.S. Senate hearing on self-driving cars and Canada's revised EV policy.

New data on China's relentless energy installations underscore warnings from Elon Musk and Jensen Huang that the nation's ...

How the Cyberspace Administration of China inadvertently made a guide to the country’s homegrown AI revolution.

At a landmark summit where China’s biggest artificial intelligence players gathered in Beijing, one question cut to the heart of the US-China race for tech supremacy: What are the chances of a Chinese ...

While artificial intelligence is reshaping how Chinese consumers shop, its immediate financial impact is happening in ...

KOID ETF offers diversified humanoid robotics exposure as China’s 2026 IPO wave reshapes holdings—capture growth across ...

Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent expirations, with industry analysts predicting licensing deals will surge to ...